Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators.
The peroxisome proliferators perfluorooctanoic acid (PFOA; 0.02% w/w), perfluorodecanoic acid (PFDA; 0.02%, w/w), nafenopin (0.125%, w/w), clofibrate (0.5%, w/w), and acetylsalicylic acid (ASA; 1%, w/w) were administered to male C57 BL/6 mice in their diet for two weeks. Parameters for Fe3+ ADP, NADPH or ascorbic acid-initiated lipid peroxidation in vitro were measured. Approximately a twofold increase in susceptibility to lipid peroxidation was obtained for all the peroxisome proliferators tested. Cotreatment of mice with the peroxisome proliferator ASA (1%, w/w) and a catalase inhibitor, 3-amino-1,2,4-triazole (AT; 0.4%, w/w) for 7 days resulted in little inhibition of peroxisome proliferation, an elevated level of H2O2 in vivo, and total inhibition of the increased susceptibility to lipid peroxidation in vitro. No increase in lipid peroxidation in vivo was observed. Certain antioxidant enzymes (DT-diaphorase, superoxide dismutase, glutathione transferase, glutathione peroxidase, and glutathione reductase) and components (ubiquinone and alpha-tocopherol) were also measured. The results showed that there was some induction of these antioxidant enzymes and components by ASA or aminotriazole, except for glutathione peroxidase and superoxide dismutase, which were inhibited. The possible involvement of oxidative stress in the carcinogenicity of peroxisome proliferators is discussed.
Cai
Y
Y
Department of Biochemistry, Wallenberg Laboratory, Stockholm University, Sweden.
Appelkvist
E L
EL
DePierre
J W
JW
D000214:Acyl Coenzyme A / Q000378:metabolism; D000640:Amitrole / Q000494:pharmacology; D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D002210:Caprylates / Q000494:pharmacology; D002374:Catalase / Q000037:antagonists & inhibitors / Q000378:metabolism; D002994:Clofibrate / Q000494:pharmacology; D003652:Decanoic Acids / Q000494:pharmacology; D004032:Diet; D005466:Fluorocarbons / Q000494:pharmacology; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008830:Microbodies / Q000187:drug effects* / Q000502:physiology; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism; D009255:Nafenopin / Q000494:pharmacology; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D010171:Palmitoyl Coenzyme A / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014451:Ubiquinone / Q000378:metabolism; D014810:Vitamin E / Q000378:metabolism
D000214:Acyl Coenzyme A; D002210:Caprylates; D003652:Decanoic Acids; D005466:Fluorocarbons; D009255:Nafenopin; D014451:Ubiquinone; D014810:Vitamin E; D010171:Palmitoyl Coenzyme A; C036567:perfluorodecanoic acid; C050466:lauroyl-coenzyme A; C023036:perfluorooctanoic acid; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D016660:NAD(P)H Dehydrogenase (Quinone); D005980:Glutathione Reductase; D005982:Glutathione Transferase; D002994:Clofibrate; D001241:Aspirin; D000640:Amitrole